Literature DB >> 9079250

The clinical spectrum of necrotising fasciitis. A review of 15 cases.

P Jarrett1, M Rademaker, M Duffill.   

Abstract

BACKGROUND: Necrotising fasciitis represents a spectrum of disease which ranges from fulminant through acute to subacute varieties. While fulminating necrotising fasciitis is a well recognised entity the subacute variety is not. AIM: To assess six years' experience of necrotising fasciitis at Waikato Hospital.
METHOD: Cases of necrotising fasciitis were identified from discharge statistics for the period 1990-1995. Records were reviewed for clinical features, predisposing factors, microbiology, histology, treatment and outcome.
RESULTS: Fifteen cases were identified of which ten were female. The average age was 55 years (range of 15-92 years). One patient presented with fulminant, eight with acute and six with subacute necrotising fasciitis. Significant blister formation was noted in eight cases. Risk factors were identified in 14 patients including trauma, renal impairment, diabetes mellitus, and various drugs including diclofenac (four patients), naproxen (one patient) and prednisone (two patients). Group A beta haemolytic streptococcus (GABHS) was identified in ten cases. Swab or tissue cultures had the highest yield for isolating the organism. Blood cultures grew GABHS in only three of 12 cases. Eight patients (53%) died. Of the survivors all but one patient required debridement and skin grafting.
CONCLUSIONS: Necrotising fasciitis is a clinical spectrum of disease. It affects a wide age group and can have associated morbidities. It is often a fatal disease. Early recognition, high dose antibiotics and surgical debridement are important in the management of the entire spectrum of necrotising fasciitis.

Entities:  

Mesh:

Year:  1997        PMID: 9079250     DOI: 10.1111/j.1445-5994.1997.tb00910.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  11 in total

1.  Necrotizing fasciitis: a comparative analysis of 56 cases.

Authors:  Jacob Ndas Legbo; Bello Bala Shehu
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

Review 2.  Necrotising fasciitis: a new management algorithm based on clinical classification.

Authors:  Paul S Carter; Paul E Banwell
Journal:  Int Wound J       Date:  2004-09       Impact factor: 3.315

3.  Multi-limb necrotizing fasciitis in a patient with rectal cancer.

Authors:  Shirley Yuk Wah Liu; Simon Siu Man Ng; Janet Fung Yee Lee
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

4.  IL-1β is an innate immune sensor of microbial proteolysis.

Authors:  Christopher N LaRock; Jordan Todd; Doris L LaRock; Joshua Olson; Anthony J O'Donoghue; Avril A B Robertson; Matthew A Cooper; Hal M Hoffman; Victor Nizet
Journal:  Sci Immunol       Date:  2016-08-19

5.  A Case of Subacute Necrotizing Fasciitis due to Serratia marcescens.

Authors:  Michael Roberts; David Crasto; David Roy
Journal:  J Clin Aesthet Dermatol       Date:  2021-01-01

Review 6.  Necrotizing fasciitis.

Authors:  Rukshini Puvanendran; Jason Chan Meng Huey; Shanker Pasupathy
Journal:  Can Fam Physician       Date:  2009-10       Impact factor: 3.275

7.  Necrotizing fascitis: an epidemiologic study of 102 cases.

Authors:  Mohammad Sadegh Fazeli; Mohammad Reza Keramati
Journal:  Indian J Surg       Date:  2008-07-30       Impact factor: 0.656

8.  Recurrent Necrotizing Fasciitis: A Case Report of Fulminant and Sub-Acute Necrotizing Fasciitis in a Diabetic Patient.

Authors:  Johannes Peters; Jean Iacobelli; Emily Ryan
Journal:  Cureus       Date:  2020-12-18

9.  Clinical Characteristics of Necrotizing Soft Tissue Infection and Early Toxic Shock-Like Syndrome Caused by Group G Streptococcus: Case Report and Review of Literature.

Authors:  Khalil Choucair; Katia El Jurdi; K James Kallail; Thomas A Moore
Journal:  Kans J Med       Date:  2021-06-21

10.  Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis.

Authors:  Kyoung-Hwa Choi; Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2008-09-16       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.